Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition

BACKGROUND: Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically significantly improved the life expectancy of chronic myeloid leukemia (CML) patients; however, resistance to TKIs remains a major clinical challenge. Although ponatinib, a third-g...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitchell, Rebecca, Hopcroft, Lisa E M, Baquero, Pablo, Allan, Elaine K, Hewit, Kay, James, Daniel, Hamilton, Graham, Mukhopadhyay, Arunima, O’Prey, Jim, Hair, Alan, Melo, Junia V, Chan, Edmond, Ryan, Kevin M, Maguer-Satta, Véronique, Druker, Brian J, Clark, Richard E, Mitra, Subir, Herzyk, Pawel, Nicolini, Franck E, Salomoni, Paolo, Shanks, Emma, Calabretta, Bruno, Holyoake, Tessa L, Helgason, G Vignir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946859/
https://www.ncbi.nlm.nih.gov/pubmed/29165716
http://dx.doi.org/10.1093/jnci/djx236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946859/
https://www.ncbi.nlm.nih.gov/pubmed/29165716
http://dx.doi.org/10.1093/jnci/djx236

Ejemplares similares